These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 17111146

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R, Gabric N.
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ.
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C.
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV, Steén B, Seregard S, Kvanta A.
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB, Sjølie AK, Møller F.
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Nov; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 10. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN.
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [Abstract] [Full Text] [Related]

  • 11. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A, Stinnett S, Fekrat S.
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [Abstract] [Full Text] [Related]

  • 12. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I.
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.
    Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU.
    Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):941-8. PubMed ID: 17186262
    [Abstract] [Full Text] [Related]

  • 14. Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration.
    Lazić R, Gabrić N, Dekaris I, Sarić B, Gavrić M.
    Coll Antropol; 2007 Jan; 31 Suppl 1():77-81. PubMed ID: 17469757
    [Abstract] [Full Text] [Related]

  • 15. Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Lazić R, Gabrić N, Dekaris I, Gavrić M, Bosnar D.
    Coll Antropol; 2007 Jan; 31 Suppl 1():71-5. PubMed ID: 17469756
    [Abstract] [Full Text] [Related]

  • 16. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU.
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF, Laud K, Fine HF, Klancnik JM, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ.
    Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
    Chen CY, Wong TY, Heriot WJ.
    Am J Ophthalmol; 2007 Mar; 143(3):510-2. PubMed ID: 17317398
    [Abstract] [Full Text] [Related]

  • 19. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment.
    Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL.
    Clin Exp Ophthalmol; 2008 Nov; 36(8):748-55. PubMed ID: 19128380
    [Abstract] [Full Text] [Related]

  • 20. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
    el Matri L, Chebil A, Kort F, Bouraoui R, Baklouti K, Mghaieth F.
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.